Literatur
- 1
Ciaroni S, Cuenoud L, Bloch A.
Clinical study to investigate the predictive parameters for the onset of atrial
fibrillation in patients with essential hypertension.
Am Heart J.
2000;
139
814-819
- 2
Dahlöf B, Devereux R B, Kjeldsen S E, Julius S, Beevers G, de Faire U, Fyrquist F,
Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm L H, Nieminen M S, Omvik P,
Oparil S, Wedel H. for the LIFE study group .
Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint
Reduction in Hypertension study (LIFE): a randomised trial against atenolol.
Lancet.
2002;
359
995-1003
- 3
Dunn F G, Chandraratna P, de Carvalho J GR, Basta L L, Fröhlich E D.
Pathophysiologic assessment of hypertensive heart disease with echocardiography.
Am J Cardiol.
1977;
39
789-795
- 4
Fuster V, Rydén L E, Asinger R W, Cannom D S, Crijns H J, Frye R L, Halperin J L,
Kay G N, Klein W W, Lévy S, McNamara R L, Prystowsky E N, Wann L S, Wyse G D.
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation:
a report of the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines and the European Society of Cardiology Committee
for Practice Guidelines and Policy Conferences.
Eur Heart J.
2001;
22
1852-1923
- 5
Gerdts E, Oikarinen L, Palmieri V, Otterstad J E, Wachtell K, Boman K, Dahlöf B, Devereux R B.
Correlates of left atrial size in hypertensive patients with left ventricular
hypertrophy. The Losartan Intervention For Endpoint Reduction in Hypertension
(LIFE) study.
Hypertension.
2002;
39
739-743
- 6
Goette A, Lendeckel U, Klein H U.
Signal transduction systems and atrial fibrillation.
Cardiovasc Research.
2002;
54
247-258
- 7
Gottdiener J S, Reda D J, Williams D W, Materson B J, Cushman W, Anderson R J. for
the VA Cooperative Study Group on Antihypertensive Agents .
Effect of single-drug therapy on reduction of left atrial size in mild to moderate
hypertension. Comparison of six antihypertensive agents.
Circulation.
1998;
98
140-148
- 8
Hannson L, Lindholm L H, Ekbom T, Dahlöf B, Lanke J, Scherstén B, Wester P O, Hedner T,
de Faire U. for the STOP-Hypertension-2 study group .
Randomised trial of old and new antihypertensive drugs in elderly patients:
cardiovascular mortality and morbidity the Swedish Trial in Old Patients with
Hypertension-2 study.
Lancet.
1999;
354
1751-1756
- 9
Hansson L, Hedner T, Lund-Johansen P, Kjeldsen S E, Lindholm L H, Syvertsen J O, Lanke J,
de Faire U, Dahlöf B, Karlberg B E. for the NORDIL Study Group .
Randomised trial of effects of calcium antagonists compared with diuretics and
ß-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic
Diltiazem (NORDIL) study.
Lancet.
2000;
356
359-365
- 10
Hansson L, Lindholm L H, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmäki K,
Dahlöf B, de Faire U, Mörlin C, Karlberg B E, Wester P O, Björck J E. for the Captopril
Prevention Project (CAPPP) study group .
Effect of angiotensin-converting-enzyme inhibition compared with conventional
therapy on cardiovascular morbidity and mortality in hypertension: the Captopril
Prevention Project (CAPPP) randomised trial.
Lancet.
1999;
353
611-616
- 11
Hennersdorf M G, Hafke G J, Steiner S, Dierkes S, Jansen A, Perings C, Strauer B E.
Determinanten des paroxysmalen Vorhofflimmerns bei Patienten mit arterieller
Hypertonie.
Z Kardiol.
2003;
92
370-376
- 12
Hennersdorf M G, Hafke G J, Steiner S, Dierkes S, Jansen A, Perings C, Strauer B E.
Reduktion des paroxysmalen Vorhofflimmerns durch Hypertrophieregression bei
arterieller Hypertonie.
Z Kardiol.
2003;
92
I/60
(Supple 1))
- 13
Kannel W B, Abbott R D, Savage D D, McNamara P M.
Epidemiologic features of chronic atrial fibrillation: the Framingham study.
N Engl J Med.
1982;
306
1018-1022
- 14
Kannel W B, Wolf P A, Benjamin E J, Levy D.
Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation:
population-based estimates.
Am J Cardiol.
1998;
82
2N-9N
- 15
Levy S, Maarek M, Coumel P, Guize L, Lekieffre J, Medvedowsky J L, Sebaoun A. for
the College of French Cardiologists .
Characterization of different subsets of atrial fibrillation in general practice
in France: the ALFA study.
Circulation.
1999;
99
3028-3035
- 16
Madrid A H, Bueno M G, Rebollo J MG, Marin I, Pena G, Bernal E, Rodriguez A, Cano L,
cano J M, Cabeza P, Moro C.
Use of Irbesartan to maintain sinus rhythm in patients with long-lasting persistent
atrial fibrillation. A prospective and randomized study.
Circulation.
2002;
106
331-336
- 17
Penado S, Cano M, Acha O, Hernandez J L, Riancho J A.
Atrial fibrillation as a risk factor for stroke recurrence.
Am J Med.
2003;
114
203-210
- 18
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation
.
Analysis of pooled data from five randomized controlled trials.
Arch Intern Med.
1994;
154
1449-1457
- 19
Schmieder R E, Martus P, Klingbeil A.
Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis
of randomized double-blind studies.
JAMA.
1996;
275
1507-1513
- 20
The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)
Investigators .
A comparison of rate control and rhythm control in patients with atrial fibrillation.
N Engl J Med.
2002;
347
1825-1833
- 21
Van Gelder I, Hagens V E, Bosker H A, Kingma J H, Kamp O, Kingma T, Said S A, Darmanata J I,
Timmermans A JM, Tijssen J GP, Crijns H JGM.
A comparison of rate control and rhythm control in patients with recurrent persistent
atrial fibrillation.
N Engl J Med.
2002;
347
1834-1840
- 22
Vaziri S M, Larson M G, Lauer M S, Benjamin E J, Levy D.
Influence of blood pressure on left atrial size. The Framingham Heart
Study.
Hypertension.
1995;
25
1155-1160
- 23
Verdecchia P, Reboldi G, Gattobigio R, Bentvoglio M, Borgioni C, Angeli F, Carluccio E,
Sardone M G, Porcellati C.
Atrial fibrillation in hypertension: predictors and outcome.
Hypertension.
2003;
41
218-223
Priv.-Doz. Dr. med. Jens Jung
Medizinische Klinik und Poliklinik, Innere Medizin III (Kardiologie/Angiologie),
Universitätskliniken des Saarlandes
66421 Homburg/Saar
Phone: 49/6841/1623001
Fax: 49/6841/1623394
Email: jung@med-in.uni-saarland.de